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subarachnoid haemorrhage and experience from 
a Swedish study. What method is preferable when 
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Abstract: Subarachnoid haemorrhage (SAH) has a high 
mortality and morbidity rate. Early SAH diagnosis allows 
the early treatment of a ruptured cerebral aneurysm, 
which improves the prognosis. Diagnostic cerebrospinal 
fluid (CSF) analyses may be performed after a negative 
computed tomography scan, but the precise analytical 
methods to be used have been debated. Here, we sum-
marize the scientific evidence for different CSF methods 
for SAH diagnosis and describe their implementation in 
different countries. The principle literature search was 
conducted using PubMed and Scopus with the search 
items “cerebrospinal fluid”, “subarachnoid haemor-
rhage”, and “diagnosis”. CSF analyses for SAH include 
visual examination, red blood cell counts, spectropho-
tometry for oxyhaemoglobin or bilirubin determination, 
CSF cytology, and ferritin measurement. The methods 
vary in availability and performance. There is a consen-
sus that spectrophotometry has the highest diagnostic 
performance, but both oxyhaemoglobin and bilirubin 
determinations are susceptible to important confound-
ing factors. Visual inspection of CSF for xanthochromia is 
still frequently used for diagnosis of SAH, but it is advised 
against because spectrophotometry has a superior diag-
nostic accuracy. A positive finding of CSF bilirubin is a 
strong indicator of an intracranial bleeding, whereas 
a positive finding of CSF oxyhaemoglobin may indicate 
an intracranial bleeding or a traumatic tap. Where spec-
trophotometry is not available, the combination of CSF 
cytology for erythrophages or siderophages and ferritin is 
a promising alternative.
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Introduction
Subarachnoid haemorrhage (SAH) accounts for approxi-
mately 5% of all strokes and has a yearly incidence of 
approximately 1 in 10,000 persons [1]. Importantly, SAH 
both has a high fatality (30%–70%) [2] and may occur at 
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an early age compared with other causes of stroke [3]. In 
the majority of cases, SAH is caused by a spontaneous 
rupture of an aneurysm in the arterial circulation of the 
brain. Typical initial symptoms are severe headache with 
a sudden onset (“thunderclap headache”), neck stiffness, 
vomiting, confusion, or loss of consciousness. Tools for 
SAH diagnosis include imaging and cerebrospinal fluid 
(CSF) analyses. There is no definite international consen-
sus on a preferred diagnostic algorithm, and procedures 
differ between countries and regions, which may have an 
impact on patients in terms of diagnosis, treatment, and 
prognosis. In this review, we aim to discuss available CSF 
methods for SAH diagnosis, clarify their strengths and 
weaknesses, and outline their use on a global scale, focus-
ing on recent guidelines and experiences from laboratory 
medicine in the UK, Germany, Sweden, the Netherlands, 
Austria, and the USA.
Methods
The literature search for this review was based on the inten-
tion to include all up-to-date studies to accurately describe 
the current scientific basis for CSF-based diagnostics of 
SAH and to illustrate the variability in methods between 
countries. We performed searches on PubMed with the 
principal search items “cerebrospinal fluid”, “subarach-
noid haemorrhage”, and “diagnosis”. We did additional 
searches with the added keywords “spectrophotometry”, 
“oxyhaemoglobin”, “methaemoglobin”, “bilirubin”, “fer-
ritin”, and “siderophages”. The database Scopus was used 
to identify more recent publications citing selected refer-
ences. From identified references, we included relevant 
clinical studies, review articles, editorials, and comments. 
Selection criteria included a judgment on the importance 
of the studies, where prospective studies, large case series, 
guidelines, and consensus documents were prioritized. 
The general search was restricted to articles in English pub-
lished after 1990, but since we aimed to review methods 
across different countries, we also included specifically 
selected articles written in other languages. We also exam-
ined older important publications that we were previously 
aware of. Finally, we also here present novel data from a 
Swedish control survey of SAH diagnostics.
The importance of early diagnosis
An incorrect initial diagnosis of SAH patients is common 
and is associated with worse prognosis [4]. SAH patients 
may initially present with less serious clinical symptoms 
(called sentinel headache) caused by a small bleeding 
(warning leak), followed by a manifest SAH, often within 
2 weeks [5]. Sentinel headache has been reported in up to 
40% of SAH patients [6]. It is of uttermost importance to 
identify these patients because interventional therapy at 
this stage may hinder a life-threatening bleeding and sig-
nificantly improve prognosis [7–9].
Diagnostic methods
Clinical examination is insufficient for SAH diagnosis. The 
most commonly used first line of investigation is noncon-
trast computed tomography (CT) of the brain. CT has an 
excellent sensitivity for SAH in the acute stage, especially 
using modern scanners, with sensitivities up to 98%–100% 
within the first hours from symptom onset [10, 11]. However, 
subtle abnormalities may not be detected by inexperienced 
or nonspecialized physicians, and expert neuroradiologists 
are not available at all hospitals [4]. However, because sub-
arachnoid blood is rapidly cleared from the brain, the sen-
sitivity drops quickly. Six hours after onset, the sensitivity 
of a CT scan for finding an SAH is approximately 86%–93% 
[11, 12], and it decreases to approximately 50% after 1 week 
(Table 1) [13]. Importantly, these figures are likely to be even 
lower when scans are evaluated by nonspecialized radi-
ologists, as is often the case in smaller hospitals or outside 
business hours. A conventional cerebral angiography is 
usually performed on patients with a positive CT scan to 
locate a possible aneurysm for interventional therapy. For 
patients with a negative CT scan where the clinical suspi-
cion remains strong, more investigations are needed [20]. 
Fluid attenuated inversion recovery (FLAIR) magnetic reso-
nance imaging (MRI) may have higher sensitivity than CT 
[21], but in clinical practice, the choice after a negative CT 
scan most often stands between a conventional cerebral 
angiography and a lumbar puncture (LP) for CSF analy-
ses. A cerebral angio graphy is resource demanding, carries 
a slight risk for stroke as a complication, and may result 
in false-positive results and unwarranted interventions 
because incidental aneurysms are found in approximately 
5% of the population [22]. These factors usually make CSF 
analyses preferred as a second-line of investigation after a 
negative CT scan.
CSF analyses
There are several widely used CSF analyses for SAH, 
with different diagnostic performance, availability, and 
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Table 1 Sensitivity and specificity for CT and biomarkers when diagnosing SAH.
Biomarker method Time since ictus Sensitivity, % Specificity, % Reference
CT  < 6 h 98–100 100 [10, 11]
CT  > 6 h 86–93 100 [11, 12]
CT  > 1 week 50 High, but accurate 
numbers are missing
[13]
Visual inspection for 
xantochromia
 > 12 h 27–47 98 [14, 15]
Red blood cell count Early in the progress or 
due to a traumatic tap
High, but accurate numbers 
are missing
Low, due to high 
false-positive rate
Oxyhaemoglobin, 
spectrophotometry
Not specified 84 42 [16]
Bilirubin, spectrophotometry Not specified 83–100 75–88 [16, 17]
Methaemoglobin, 
spectrophotometry
Not specified 66 79 [16]
Ferritin > 15 ng/mL Not specified 95 95 [18]
Siderophages  > 24 h High, but accurate numbers 
are missing
High, but accurate 
numbers are missing
[19]
technical requirements. A consequence in clinical prac-
tice of differences between methods and how they are 
implemented is that patients may receive different dia-
gnoses and treatments at different hospitals.
Visual inspection
The most basic CSF method for SAH is the visual evalua-
tion of discoloration. For this, the sample is usually cen-
trifuged and the supernatant compared with a tube of 
water, held against a well-illuminated white background. 
Normal CSF is uncolored, and transparent. After an SAH, 
a yellowish or reddish tint is seen due to bilirubin (called 
xanthochromia) or oxyhaemoglobin. According to a 
survey from 2002, most US laboratories use visual assess-
ment of xanthochromia as their main CSF analysis of SAH 
[23]. However, the sensitivity of the human color vision is 
not sufficient to detect a very small amount of bilirubin, 
which may appear as transparent as water [14, 24]. The 
human eye also has difficulty in assessing xanthochromia 
of a predominantly red fluid, which makes it problematic 
to visually distinguish a red sample after a traumatic tap 
from a bilirubin-rich sample after an SAH. A traumatic 
tap may occur when the LP needle punctuates a blood 
vessel. This has been estimated to happen in 10%–20% 
of LPs but may be even more frequent depending on the 
definitions of the cutoff towards a normal CSF erythrocyte 
count [25–29]. A traumatic tap introduces erythrocytes 
in the CSF, which may undergo in vitro lysis and release 
their oxyhaemoglobin content. On visual inspection, 
approximately 80% of CSF samples with significant bili-
rubin levels seem red rather than yellow due to the pres-
ence of oxyhaemoglobin [30]. In sum, visual inspection 
has poor diagnostic sensitivity for SAH (Table 1) [14, 15] 
and a higher proportion of laboratory technicians identify 
bilirubin when using a spectrophotometer compared with 
visual inspection [24, 31]. The subjectivity of visual evalu-
ation also makes it difficult to perform comparisons over 
time. There are also other possible causes of CSF disco-
loration, as explained in the Confounding Factors section.
Red blood cell count
In principle, normal CSF should not contain erythrocytes, 
but the red blood cell count expected in CSF after an SAH, 
differentiating it from a traumatic tap, is not well defined. 
Cell counts are sometimes performed on serial tubes, to 
detect declining red blood cell counts, indicating a trau-
matic tap (the so-called three-tube method). However, 
because a traumatic tap may result in discontinuing and 
resuming bleedings and may occur also in the presence of 
an SAH, the serial tube method is unreliable [32, 33].
Spectrophotometry
Spectrophotometry is used to detect the absorption spec-
trum of CSF pigments, and the presence of different bio-
markers may be estimated from the absorption curve. 
It is a rapid ( < 1 min) technique that requires a small 
sample amount (50–500 µL) [28]. Because sensitivity and 
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specificity vary for different markers that may be elevated 
depending on the duration since symptom onset, the labo-
ratory technician must know the time point of symptom 
debut, sampling, and centrifugation to perform a sound 
interpretation (Table 1).
Oxyhaemoglobin
After an SAH, the erythrocytes in the CSF will gradually 
lyse and release their intracellular haemoglobin. This 
process starts shortly (2–4 h) after the bleeding, and oxy-
haemoglobin can be detected in CSF from approximately 
2–12  h after ictus [34]. Oxyhaemoglobin, the oxygen-
ated form of haemoglobin, has an absorbance maximum 
around 415 nm, in the violet region of the optical spectrum 
(Figure 1A) [28]. Minor secondary absorbance peaks, some-
times referred to as Soret bands, may be detected at 540 
and 580 nm, in the green region of the optical spectrum.
Bilirubin
Oxyhaemoglobin is metabolized to bilirubin through 
enzymatic reactions by macrophages in vivo. This does 
not occur in vitro in tapped CSF (except in samples with 
very high white blood cell count), which strongly reduces 
the risk for false-positive results caused by a traumatic 
tapping. Bilirubin has a broad maximum absorption peak 
in the blue region of the optical spectrum at 450–460 nm 
[28]. On spectrophotometry of an acute bleeding, where 
oxyhaemoglobin is still present in high concentrations, 
bilirubin may be visible as a gentle slope to the right of the 
sharp oxyhaemoglobin peak (Figure 1B). As an alternative 
to using a spectrophotometer, CSF bilirubin may also be 
measured by the modification of the direct diazo methods 
used for bilirubin measurements in serum or plasma. This 
has been suggested as a screening instrument to iden-
tify samples that need to be further analyzed by spectro-
photometry [35, 36], but difficulties regarding technical 
analyses and method standardization may hinder a broad 
implementation of this tentative approach [37].
Methaemoglobin
Methaemoglobin is haemoglobin with ferric (Fe3+) instead 
of ferrous iron (Fe2+) in the haem group, with a broad 
absorbance maximum peak at 403–410 nm. Normally, 
methaemoglobin is present in very small amounts, but 
it has been reported in CSF of patients with subdural 
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Figure 1 Spectrophotometry of oxyhaemoglobin (A) and bilirubin 
(B) slope.
haematoma or an enclosed bleeding, giving the CSF a 
brownish color [38]. A spontaneous oxidation of the haem 
group occurs around 10 days after a bleed, irrespective of 
cause [39], which may be useful to distinguish between a 
traumatic tap and a cerebral haemorrhage [40].
Ferritin
Ferritin is an iron-storage protein complex that removes 
toxic iron released from the metabolized haemoglobin. 
The production of this large protein takes some time, and 
therefore, CSF ferritin has a lower sensitivity in the first 
hours after SAH and is not advocated for diagnostic use 
at an early stage [41, 42]. A first increase is possibly due 
to the activation of macrophages. It takes approximately 
3 days for the CSF ferritin levels to consistently increase 
and 7–10  days to reach over 1000 ng/mL [43]. For com-
parison, control CSF has been reported to have an average 
ferritin level of approximately 4 ng/mL, whereas CSF con-
taminated by a traumatic LP has been reported to have 
an average ferritin level of approximately 9 ng/mL [43]. 
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One conservative reference limit that has been proposed 
is 12 ng/mL [44], and in a prospective study, a cutoff of 
15 ng/mL achieved 95% sensitivity and specificity for SAH 
(Table 1) [18]. Importantly, CSF ferritin levels remain high 
long after CSF bilirubin decrease or become undetectable 
[42, 43].
Siderophages
SAH induces an inflammatory response that includes 
macrophage activation. Macrophages that have consumed 
erythrocytes develop haemosiderin storage and are called 
siderophages. Cytological finding of CSF siderophages 
have a low sensitivity within the first 3  days after an 
intracranial bleeding, making them unsuitable for early 
diagnosis, but later in the process, they have high sensi-
tivity and specificity, and they may even be detected for 
several months after an insult (Table 1) [32, 19]. In combi-
nation with erythrophages (macrophages that do not have 
haemosiderin inside), they can give important clues about 
the age and dynamics of the bleeding [45].
Other methods
Other CSF biomarkers tested for SAH diagnosis require 
further evaluation (for example, urine test stripes for 
rapid detection of red blood cells in CSF [46]) or have 
shown inconclusive results (for example, CSF D-dimer [12, 
47, 48]).
Regional practices
The implementation of the methods used to diagnose SAH 
after a negative CT scan outlined above differs between 
countries and regions, even among specialized centers. 
Here, we experiences from different countries, focusing 
on official UK guidelines, a recently completed survey 
among Swedish laboratories, and the authors own experi-
ences from practice in Germany, Austria, Switzerland, and 
USA.
United Kingdom
The UK National External Quality Assessment Service 
(NEQAS) guidelines stress the use of spectrophotometry 
and have reduced the use of visual assessment for SAH 
diagnosis in the UK [49, 50]. These guidelines emphasize 
the use of bilirubin because this is solely produced in 
vivo, as opposed to oxyhaemoglobin and methaemo-
globin [50], reducing the risks for false-positive results. 
Accordingly, the UK guidelines state that the sampling 
should be no < 12  h after the possible bleeding. The UK 
guidelines advocate scanning between 350 and 600 nm to 
allow interpretation of the curve for bilirubin, oxyhaemo-
globin, and methaemoglobin (which is considered a prob-
able artefact of oxyhaemoglobin conversion and given the 
same significance as oxyhaemoglobin). The net biliru-
bin absorbance (NBA) is calculated according to Chalm-
ers’ modified method [51], but the laboratory technician 
should also measure the net oxyhaemoglobin absorbance 
(NOA) at the maximum oxyhaemoglobin absorbance. The 
absence of bilirubin and oxyhaemoglobin (NBA ≤  0.007 AU 
and NOA ≤  0.02 AU) is reported as “no evidence to support 
SAH”. Small amounts of oxyhaemoglobin (NBA ≤  0.007 AU 
and 0.1 AU > NOA > 0.002 AU) is also reported as “no evi-
dence to support SAH”, but an oxyhaemoglobin peak 
large enough to allow impairment of bilirubin detection 
(NBA ≤  0.007 AU and NOA ≥  0.1 AU) is reported as “SAH not 
excluded”. If bilirubin is detected alone (NBA > 0.007 AU 
and NOA ≤  0.02 AU or NOA > 0.02 but with no visible oxy-
haemoglobin peak), the laboratory technician considers 
the serum bilirubin and CSF protein levels because these 
may give false-positive bilirubin results. If serum bilirubin 
is low ( ≤  20 μmol/L), the result is reported as “consistent 
with SAH”, and if serum bilirubin is high ( > 20 μmol/L), the 
NBA is adjusted accordingly and reported as “consistent 
with SAH” (if still increased) or “not supportive of SAH” 
(if the increase depended on serum bilirubin). Increased 
bilirubin (NBA > 0.007 AU) in the presence of elevated CSF 
protein levels ( > 1.0 g/L) is reported as a possible SAH, but 
other sources of increased CSF bilirubin must then also 
be considered. Finally, a concurrent finding of bilirubin 
and oxyhaemoglobin (NBA > 0.007 AU and NOA > 0.02 AU 
with visible oxyhaemoglobin peak) is reported as “con-
sistent with SAH”. This scheme has become influential, 
but its use is not trivial, and it requires trained staff and a 
substantial through-flow of samples to maintain observer 
skills.
Sweden
During 2010, a survey of CSF analyses in SAH investiga-
tions in Sweden was performed. A questionnaire was sent 
out to all Swedish laboratories participating in quality 
control programs organized by the External Quality 
Assurance in Laboratory Medicine in Sweden (EQUALIS) 
(n = 24). Twenty-two laboratories reported that they used 
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spectrophotometry as their main method. Ten of these 
measured absorbance at 415  nm (with or without a full 
curve); five laboratories stated that they used spectropho-
tometry but did not further specify how; five laboratories 
followed the UK NEQAS guidelines; two laboratories 
measured absorbance at 415  nm plus direct measure-
ment of CSF bilirubin; and two laboratories evaluated 
the samples visually and did cell counts. To investigate 
if these differences may result in different patient man-
agement, two survey samples were sent out (prepared at 
the Clinical Neurochemistry Laboratory in Mölndal by de-
identified CSF samples from the routine workflow). Each 
sample had a (fictional) medical history. The first sample 
was presented as “male, 34  years old, acute headache, 
debuted 8 h before sampling. Bleeding?” Spectrophotom-
etry at Mölndal showed a distinct oxyhaemoglobin peak 
(absorbance, 415 nm, 0.16 AU; Figure 2A). Of 17 responding 
laboratories, 11 reported that SAH could not be excluded 
(9 specifically answered that the result also was consist-
ent with a traumatic tap), three reported that the result 
indicated SAH, and two reported that SAH was unlikely. 
The second sample was presented as “woman, 66 years 
old, has been feeling uncomfortable since 2–3 days. In 
the beginning, she also had a headache. Bleeding?” 
Spectrophotometry at Mölndal showed a distinct biliru-
bin peak (absorbance, 451 nm, 0.043 AU; Figure 2B). Of 
15 responding laboratories, eight reported that the result 
indicated SAH if serum bilirubin < 20 μmol/L, five reported 
that the result indicated SAH, 1 reported that the result 
excluded SAH, and one responded that results without 
accompanying blood samples were not interpreted. In 
sum, for a sample with a significant spectrophotomet-
ric oxyhaemoglobin peak 8 h after headache onset, SAH 
was reported as the only interpretation by three labora-
tories and unlikely by three laboratories. A more careful 
interpretation, that SAH could not be excluded but that a 
traumatic tap must also be considered, was only reported 
by 11 of 17 laboratories. The reports were more consistent 
when the sample was dominated by a significant biliru-
bin peak, where only 1 of 15 laboratories answered that 
the results excluded SAH.
Germany, Austria, Switzerland, the Netherlands,  
and USA
In the German-speaking countries (Germany, Austria, and 
Switzerland), the use of absorbance spectrophotometry 
for SAH diagnostics is still uncommon. Instead, CSF fer-
ritin measurement is the method of choice at most centers 
because it is easily available on the routine laboratory 
instruments that already measures CSF total protein, 
glucose, and lactate. Current guidelines by the German 
Society of CSF Diagnostics and Clinical Neurochemistry 
(DGLN) suggest visual inspection including the “three-
tube method”, cell differentiation, and measurement of 
ferritin when looking for an SAH [52], but measuring the 
absorbance with a spectrophotometer was recently named 
as alternative method [45].
In the Netherlands, national guidelines for CSF 
analyses following SAH are still awaited at time of 
writing. The Erasmus Medical Center has adopted the 
UK NEQAS guidelines using Chalmers calculation. A 
computer-based iterative method to interpret spectro-
photometric results (described below) have been deve-
loped by Dutch researchers [16]. A recent review from 
a leading national center on SAH recommended visual 
analysis [53], which resulted in an educative scientific 
exchange [54–57].
In the USA, LP is acknowledged for SAH examina-
tion (visual inspection and cell counts) after a negative 
CT scan, but spectrophotometry is still uncommon [58]. 
There is not a formal quality control program in use for 
CSF bilirubin testing because it is not a procedure prac-
ticed widely in the country.
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Confounding factors
All CSF analyses described above are subject to con-
founding factors related to the LP, sample handling, or 
interpretation.
Timing of the LP
The timing of the LP in relation to symptom onset has a 
pivotal impact on all results (Figure 3). CSF production and 
turnover replaces the entire CSF volume four times each 
day [59], making it a dynamic compartment. Erythrocytes 
may be found in the lumbar region approximately 2  h 
after an intracranial bleeding [38]. Oxyhaemoglobin also 
starts to appear around this time point, whereas bilirubin 
first shows 12 h after the bleeding [50, 60]. For the detec-
tion of oxyhaemoglobin, it is recommended that sampling 
is done no sooner than 6 h after symptom onset, when a 
large enough CSF volume has passed from intracranial 
areas to the lumbar sack, making the lumbar sample rep-
resentative. Because the oxyhaemoglobin peak diminishes 
over time, an isolated oxyhaemoglobin peak without any 
signs of bilirubin in a sample taken more than 12 h after 
symptom onset suggests contamination by a traumatic tap.
Sample transport and storage
The transport of the sample to the laboratory should be 
done swiftly, and not in a pneumatic tube, to avoid in 
vitro haemolysis [61] because this may lead to false-pos-
itive results for oxyhaemoglobin and impair the ability 
to detect bilirubin. At the laboratory, the sample must be 
centrifuged as soon as possible if a spectrophotometry 
analysis should be done. If the red cell count is the method 
in use, centrifugation should not be done. UK guidelines 
[50] and others [62] suggest centrifugation within 1 h after 
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Figure 3 Schematic time-dependent dynamics of CSF biomarkers 
for SAH.
sampling, whereas Swedish laboratories are generally 
recommended to centrifuge within 30 min. These cutoffs 
are arbitrary, and in our clinical experience, haemolysis 
may start even within 30 min in some samples, whereas it 
may take several hours in other samples. The supernatant 
should be stored at 4°C in the dark until analysis to avoid 
ultraviolet light-dependent degradation of bilirubin, pro-
ducing false-negative results [63].
False-positive bilirubin
Bilirubin may be false positive due to hyperbilirubine-
mia (a serum sample should therefore be taken together 
with CSF to allow adjustment for this), significant blood-
brain barrier damage, malignancies, or treatment with 
rifampicin [28, 64].
Use the least bloody sample
Although the “three-tube method” is susceptible to false 
results, serial tubes may be useful because an initial bloody 
sample portion may be discarded immediately and the 
least bloodstained sample used for analysis (at the labora-
tory, red blood cell counts may be done on partial samples 
from all available tubes, and the sample with the lowest 
count used for spectrophotometry). A clearing between the 
first tube and the last tube cannot exclude SAH. In a study 
by Heasley et al. [65], clearing, defined as a 25% reduction 
of RBC between the first tube and the fourth tube, was 
present even in cases with ruptured aneurysms.
Interpreting the spectrophotometry
Spectrophotometry is generally appreciated as the gold 
standard method for CSF analyses of SAH, but there is 
no definite consensus on curve interpretation, neither in 
terms of the roles of oxyhaemoglobin vs. bilirubin nor on 
definitions of pathological cutoffs. One study [17] found 
low specificity and positive predictive value of spectro-
photometry, recommending CT angiography as an alter-
native. However, such studies have typically not carefully 
adjusted for the presence of a traumatic tap masking the 
presence of bilirubin [66]. Gunawardena et al. suggest that 
patients with oxyhaemoglobin alone and a high suspicion 
of SAH may benefit from angiography, although the risk 
for aneurysm is low [67]. A result positive for bilirubin, 
with or without oxyhaemoglobin, means a high risk for a 
bleeding aneurysm and should lead to angiography if the 
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CSF bilirubin cannot be explained otherwise. According 
to the UK guidelines, elevated oxyhaemoglobin and bili-
rubin is reported as consistent with SAH [50], irrespective 
of CSF protein levels [68]. A problem is that a traumatic 
tap may lead to increased oxyhaemoglobin and together 
with either elevated CSF proteins or hyperbilirubinemia 
may lead to a spectroscopy result that is reported as “con-
sistent with SAH” [69, 70]. If bilirubin is elevated without 
a visible oxyhaemoglobin peak and CSF protein levels are 
raised, meningitis or other diagnoses are more likely [68]. 
It is therefore important that the clinicians carefully con-
sider the clinical history, serum bilirubin concentrations, 
CSF protein levels as well as the number of LP attempts.
Visual interpretation of the curve is prone to interob-
server variability. Chalmers and Kiley [71] have described 
a standardized method to calculate NBA using a baseline 
drawn as tangent to the curve between 360 and 530 nm 
and measuring the distances from the baseline to the 
curve at 415 and 440 nm to compensate for the oxyhae-
moglobin load. The method was later modified by Chalm-
ers [51], using a measurement at 476 nm only, where the 
influence from oxyhaemoglobin is so small that the bili-
rubin measurement does not need compensation. Viljoen 
et al. [72] have investigated the imprecision when calculat-
ing the NBA according to Chalmers’ modification. When 
measuring the within-operator variability, they found a 
variation of 17% at the medical decision level suggested 
by the UK guidelines. To minimize the imprecision, they 
suggested the use of a software-assisted measurement. 
Recently, Collet et al. [73] proposed such a method, a web-
based software to interpret CSF pigments, that is based 
on the NEQAS guidelines [73]. For clinicians and labora-
tory personnel, it is important that they are aware of the 
variability in the NBA calculation, especially when calcu-
lated on a single NBA cutpoint, as recommended in the 
UK guidelines [72, 74]. An iterative (step-by-step) method, 
where a computer program calculates the contributions 
from methaemoglobin, oxyhaemoglobin, and bilirubin 
from absorbance at 405, 414, and 455 nm, respectively, 
may be used [16], but it has lower diagnostic accuracy 
than a derivative method, using a standard of serial dilu-
tions of CSF with known bilirubin concentrations [75], 
compared with angiography as gold standard.
Towards an optimal CSF biomarker 
for SAH?
There is a consensus that spectrophotometry has the 
highest diagnostic performance of CSF methods for SAH 
analyses, but visual evaluation of CSF samples is still 
widely in clinical use in some countries. The major dis-
advantages of spectrophotometry are equipment cost, 
the need for trained staff to interpret results, and the 
lack of a global consensus on the optimal usage of the 
method. In the absence of compelling study data defin-
ing its cost-benefit, the costs involved in purchase of the 
spectrophotometer system, in the maintenance of the 
equipment, and the skill level of the individuals who 
would perform the testing are hard to justify in some 
countries, including the USA. Bilirubin has a strong 
positive predictive value for SAH, but relying solely on 
bilirubin, ignoring oxyhaemoglobin as an indicator of 
bleeding, requires an approximately 12-h wait between 
symptom debut and CSF tapping, which may be a logistic 
problem with prolonged stay for the patient at the emer-
gency ward, and in some cases, a medical risk because 
a delayed investigation increases the risk for an early 
rebleeding [76, 77]. CSF ferritin is a promising method 
but carries a risk for false-negative results early after a 
bleeding. Finally, in rare cases with negative CT scans 
and CSF examinations, transcranial Doppler sonogra-
phy and CT/MRI angiography have been reported to be 
useful [78].
Conclusions
Visual inspection of CSF for xanthochromia is still fre-
quently used for CSF-based diagnosis of SAH, but it is 
advised against because spectrophotometric methods 
have superior diagnostic accuracy. Positive findings of CSF 
bilirubin in the early stages or of CSF ferritin in the later 
stages are strong indicators of an intracranial bleeding. A 
positive finding of CSF oxyhaemoglobin may indicate an 
intracranial bleeding or a traumatic tap. Rigorous control 
of confounding factors may reduce the risk for false results.
Studies that compare different methods have not been 
done, and therefore, it is hard to evaluate what method is 
preferable. Many factors (confounding factors as well as 
costs, knowledge of the staff, etc.) have to be accounted 
for in such a comparison. Today, deciding what method 
to use in a certain laboratory seems to be dependent on 
local knowledge, opinions, and thinking. In sum, more 
of a proven experience rather than evidence decides how 
the CSF sample will be handled, but guidelines built on 
research are being used more and more. However, the 
overall variability described in this review calls for the 
establishment of a global proficiency testing program for 
CSF-based SAH diagnostics.
Nagy et al.: Diagnosis of subarachnoid haemorrhage      2081
Conflict of interest statement
Author’s conflict of interest disclosure: The author stated 
that there are no conflicts of interest regarding the publi-
cation of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Received November 17, 2012; accepted March 12, 2013; previously 
published online May 9, 2013
References
1. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke 
epidemiology: a review of population-based studies of 
incidence, prevalence, and case-fatality in the late 20th century. 
Lancet Neurol 2003;2:43–53.
2. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates 
and functional outcome after subarachnoid hemorrhage: a 
systematic review. Stroke 1997;28:660–4.
3. Johnston SC, Selvin S, Gress DR. The burden, trends, and 
demographics of mortality from subarachnoid hemorrhage. 
Neurology 1998;50:1413–8.
4. Edlow JA, Caplan LR. Avoiding pitfalls in the diagnosis of 
subarachnoid hemorrhage. N Engl J Med 2000;342:29–36.
5. de Falco FA. Sentinel headache. Neurol Sci 2004;25:S215–7.
6. Polmear A. Sentinel headaches in aneurysmal subarachnoid 
haemorrhage: what is the true incidence? A systematic review. 
Cephalalgia 2003;23:935–41.
7. Jakobsson KE, Saveland H, Hillman J, Edner G, Zygmunt S, Brandt 
L, et al. Warning leak and management outcome in aneurysmal 
subarachnoid hemorrhage. J Neurosurg 1996;85:995–9.
8. Gambhir S, O’Grady G, Koelmeyer T. Clinical lessons and risk 
factors from 403 fatal cases of subarachnoid haemorrhage.  
J Clin Neurosci 2009;16:921–4.
9. Mayer PL, Awad IA, Todor R, Harbaugh K, Varnavas G, Lansen 
TA, et al. Misdiagnosis of symptomatic cerebral aneurysm. 
Prevalence and correlation with outcome at four institutions. 
Stroke 1996;27:1558–63.
10. van der Wee N, Rinkel GJ, Hasan D, van Gijn J. Detection of 
subarachnoid haemorrhage on early CT: is lumbar puncture still 
needed after a negative scan? J Neurol Neurosurg Psychiatry 
1995;58:357–9.
11. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Emond M, 
Symington C, et al. Sensitivity of computed tomography 
performed within six hours of onset of headache for diagnosis 
of subarachnoid haemorrhage: prospective cohort study. BMJ 
2011;343:d4277.
12. Morgenstern LB, Luna-Gonzales H, Huber JC Jr, Wong SS, 
Uthman MO, Gurian JH, et al. Worst headache and subarachnoid 
hemorrhage: prospective, modern computed tomography and 
spinal fluid analysis. Ann Emerg Med 1998;32:297–304.
13. van Gijn J, van Dongen KJ. The time course of aneurysmal 
haemorrhage on computed tomograms. Neuroradiology 
1982;23:153–6.
14. Sidman R, Spitalnic S, Demelis M, Durfey N, Jay G. Xanthrochromia? 
By what method? A comparison of visual and spectrophotometric 
xanthrochromia. Ann Emerg Med 2005;46:51–5.
15. Arora S, Swadron SP, Dissanayake V. Evaluating the sensitivity 
of visual xanthochromia in patients with subarachnoid 
hemorrhage. J Emerg Med 2010;39:13–6.
16. Duiser HJ, Roelandse FW, Lentjes EG, van Loon J, Souverijn JH, 
Sturk A. Iterative model for the calculation of oxyhemoglobin, 
methemoglobin, and bilirubin in absorbance spectra of 
cerebrospinal fluid. Clin Chem 2001;47:338–41.
17. Wood MJ, Dimeski G, Nowitzke AM. CSF spectrophotometry 
in the diagnosis and exclusion of spontaneous subarachnoid 
haemorrhage. J Clin Neurosci 2005;12:142–6.
18. Wick M, Pfister HW. Ferritin and iron metabolism in 
cerebrospinal fluid (CSF) subarachnoid hemorrhage (SAH). IFCC 
– WorldLab ‘99, Firenze, Italy, 1999:77.
19. Veuger AJ, Kortbeek LH, Booij AC. Siderophages in differen-
tiation of blood in cerebrospinal fluid. Clin Neurol Neurosurg 
1977;80:46–56.
20. Edlow JA, Wyer PC. Evidence-based emergency medicine/clinical 
question. How good is a negative cranial computed tomographic 
scan result in excluding subarachnoid hemorrhage? Ann Emerg 
Med 2000;36:507–16.
21. Mitchell P, Wilkinson ID, Hoggard N, Paley MN, Jellinek DA, 
Powell T, et al. Detection of subarachnoid haemorrhage with 
magnetic resonance imaging. J Neurol Neurosurg Psychiatry 
2001;70:205–11.
22. Unruptured intracranial aneurysms – risk of rupture and risks of 
surgical intervention. International Study of Unruptured Intracra-
nial Aneurysms Investigators. N Engl J Med 1998;339:1725–33.
23. Edlow JA, Bruner KS, Horowitz GL. Xanthochromia. Arch Pathol 
Lab Med 2002;126:413–5.
24. Petzold A, Keir G, Sharpe TL. Why human color vision cannot 
reliably detect cerebrospinal fluid xanthochromia. Stroke 
2005;36:1295–7.
25. Shah KH, Edlow JA. Distinguishing traumatic lumbar puncture from 
true subarachnoid hemorrhage. J Emerg Med 2002;23:67–74.
26. Marton KI, Gean AD. The spinal tap: a new look at an old test. 
Ann Intern Med 1986;104:840–8.
27. Eskey CJ, Ogilvy CS. Fluoroscopy-guided lumbar puncture: 
decreased frequency of traumatic tap and implications for the 
assessment of CT-negative acute subarachnoid hemorrhage. 
AJNR Am J Neuroradiol 2001;22:571–6.
28. Petzold A, Sharpe LT, Keir G. Spectrophotometry for cerebrospinal 
fluid pigment analysis. Neurocrit Care 2006;4:153–62.
29. Shah KH, Richard KM, Nicholas S, Edlow JA. Incidence of 
traumatic lumbar puncture. Acad Emerg Med 2003;10:151–4.
30. Petzold A, Keir G, Sharpe LT. Spectrophotometry for xantho-
chromia. N Engl J Med 2004;351:1695–6.
31. Linn FH, Voorbij HA, Rinkel GJ, Algra A, van Gijn J. Visual inspection 
versus spectrophotometry in detecting bilirubin in cerebrospinal 
fluid. J Neurol Neurosurg Psychiatry 2005;76:1452–4.
32. Vermeulen M. Subarachnoid haemorrhage: diagnosis and 
treatment. J Neurol 1996;243:496–501.
2082      Nagy et al.: Diagnosis of subarachnoid haemorrhage
33. Buruma OJ, Janson HL, Den Bergh FA, Bots GT. Blood-stained 
cerebrospinal fluid: traumatic puncture or haemorrhage?  
J Neurol Neurosurg Psychiatry 1981;44:144–7.
34. Cruickshank AM. ACP Best Practice No 166: CSF spectropho-
tometry in the diagnosis of subarachnoid haemorrhage. J Clin 
Pathol 2001;54:827–30.
35. Chao CY, Florkowski CM, Fink JN, Southby SJ, George PM. 
Prospective validation of cerebrospinal fluid bilirubin in suspected 
subarachnoid haemorrhage. Ann Clin Biochem 2007;44:140–4.
36. Ungerer JP, Southby SJ, Florkowski CM, George PM. Automated 
measurement of cerebrospinal fluid bilirubin in suspected 
subarachnoid hemorrhage. Clin Chem 2004;50:1854–6.
37. Beetham R. CSF bilirubin-spectrophotometry or direct 
measurement? Ann Clin Biochem 2007;44:99–100.
38. Barrows LJ, Hunter FT, Banker BQ. The nature and clinical  
significance of pigments in the cerebrospinal fluid. Brain 
1955;78:59–80.
39. Wahlgren NG, Lindquist C. Haem derivatives in the cerebrospinal 
fluid after intracranial haemorrhage. Eur Neurol 1987;26:216–21.
40. Trbojevic-Cepe M, Vogrinc Z, Brinar V. Diagnostic significance of 
methemoglobin determination in colorless cerebrospinal fluid. 
Clin Chem 1992;38:1404–8.
41. Watson ID, Beetham R, Fahie-Wilson MN, Holbrook IB, O’Connell 
DM. What is the role of cerebrospinal fluid ferritin in the diagnosis 
of subarachnoid haemorrhage in computed tomography-negative 
patients? Ann Clin Biochem 2008;45:189–92.
42. Petzold A, Worthington V, Pritchard C, Appleby I, Kitchen N, 
Smith M. The longitudinal profile of bilirubin and ferritin in 
the cerebrospinal fluid following a subarachnoid hemorrhage: 
diagnostic implications. Neurocrit Care 2009;11:398–402.
43. Petzold A, Worthington V, Appleby I, Kerr ME, Kitchen N,  
Smith M. Cerebrospinal fluid ferritin level, a sensitive 
diagnostic test in late-presenting subarachnoid hemorrhage.  
J Stroke Cerebrovasc Dis 2011;20:489–93.
44. Keir G, Tasdemir N, Thompson EJ. Cerebrospinal fluid ferritin 
in brain necrosis: evidence for local synthesis. Clin Chim Acta 
1993;216:153–66.
45. Tumani H, Petzold A, Wick M, Kuhn HJ, Uhr M, Otto M, et al. 
[Cerebrospinal fluid-based diagnostics of CT-negative 
subarachnoid haemorrhage]. Nervenarzt 2010;81:973–9.
46. Marshall RA, Hejamanowski C. Urine test strips to exclude 
cerebral spinal fluid blood. West J Emerg Med 2011;12:63–6.
47. Page KB, Howell SJ, Smith CM, Dabbs DJ, Malia RG, Porter NR, 
et al. Bilirubin, ferritin, D-dimers and erythrophages in the 
cerebrospinal fluid of patients with suspected subarachnoid 
haemorrhage but negative computed tomography scans. J Clin 
Pathol 1994;47:986–9.
48. Lang DT, Berberian LB, Lee S, Ault M. Rapid differentiation of 
subarachnoid hemorrhage from traumatic lumbar puncture 
using the D-dimer assay. Am J Clin Pathol 1990;93:403–5.
49. UK National External Quality Assessment Scheme for Immuno-
chemistry Working Group. National guidelines for analysis of 
cerebrospinal fluid for bilirubin in suspected subarachnoid 
haemorrhage. Ann Clin Biochem 2003;40:481–8.
50. Cruickshank A, Auld P, Beetham R, Burrows G, Egner W, 
Holbrook I, et al. Revised national guidelines for analysis of 
cerebrospinal fluid for bilirubin in suspected subarachnoid 
haemorrhage. Ann Clin Biochem 2008;45:238–44.
51. Chalmers AH. Cerebrospinal fluid xanthochromia testing 
simplified. Clin Chem 2001;47:147–8.
52. Petereit HF, Sindern E, Wick M. Leitlinien und Methodenkatalog 
der Deutschen Gesellschaft für Liquordiagnostik und Klinische 
Neurochemie. Heidelberg: Springer, 2007.
53. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. 
Lancet 2007;369:306–18.
54. Batra YK, Rajeev S. Subarachnoid haemorrhage. Lancet 
2007;369:903.
55. Kreitschmann-Andermahr I, Schneider HJ. Subarachnoid 
haemorrhage. Lancet 2007;369:903–4.
56. Jolobe OM. Subarachnoid haemorrhage. Lancet 2007;369:904.
57. Holbrook I, Beetham R, Cruickshank A, Keir G, Watson I. 
Subarachnoid haemorrhage. Lancet 2007;369:904.
58. Edlow JA, Panagos PD, Godwin SA, Thomas TL, Decker WW. 
American College of Emergency P. Clinical policy: critical issues 
in the evaluation and management of adult patients presenting 
to the emergency department with acute headache. Ann Emerg 
Med 2008;52:407–36.
59. Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, 
Silverberg GD. Multiplicity of cerebrospinal fluid functions: 
new challenges in health and disease. Cerebrospinal Fluid Res 
2008;5:10.
60. Morgan CJ, Pyne-Geithman GJ, Jauch EC, Shukla R, Wagner 
KR, Clark JF, et al. Bilirubin as a cerebrospinal fluid marker of 
sentinel subarachnoid hemorrhage: a preliminary report in pigs. 
J Neurosurg 2004;101:1026–9.
61. Wenham PR, Hanson T, Ashby JP. Interference in spectropho-
tometric analysis of cerebrospinal fluid by haemolysis induced 
by transport through a pneumatic tube system. Ann Clin 
Biochem 2001;38:371–5.
62. Graves P, Sidman R. Xanthochromia is not pathognomonic for 
subarachnoid hemorrhage. Acad Emerg Med 2004;11:131–5.
63. Foroughi M, Parikh D, Wassell J, Hatfield R. Influence of light 
and time on bilirubin degradation in CSF spectrophotometry for 
subarachnoid haemorrhage. Br J Neurosurg 2010;24:401–4.
64. Lo BM, Quinn SM. Gross xanthochromia on lumbar puncture 
may not represent an acute subarachnoid hemorrhage. Am J 
Emerg Med 2009;27:621–3.
65. Heasley DC, Mohamed MA, Yousem DM. Clearing of red blood 
cells in lumbar puncture does not rule out ruptured aneurysm 
in patients with suspected subarachnoid hemorrhage 
but negative head CT findings. AJNR Am J Neuroradiol 
2005;26:820–4.
66. Watson ID, Beetham R, Keir G, Cruickshank AM, Holbrook IB, 
Fahie-Wilson MN, et al. Cerebrospinal fluid spectrophotometry 
of bilirubin, not the Xanthochromic Index, for the detection 
of CT-negative sub-arachnoid haemorrhage. J Clin Neurosci 
2007;14:608–9.
67. Gunawardena H, Beetham R, Scolding N, Lhatoo SD. 
Is cerebrospinal fluid spectrophotometry useful in CT 
scan-negative suspected subarachnoid haemorrage? Eur Neurol 
2004;52:226–9.
68. Cruickshank AM, Proteins UNSAGfEQAoC, Biochemistry. 
Revision of national guidelines for cerebrospinal fluid analysis 
in suspected subarachnoid haemorrhage. Ann Clin Biochem 
2008;45:236–7.
69. Sulaiman RA, Gama R. Pitfalls in cerebrospinal fluid 
spectroscopy results for the diagnosis of subarachnoid 
haemorrhage. Br J Neurosurg 2010;24:726.
70. Griffiths MJ, Ford C, Gama R. Revised national guidelines for 
the analysis of cerebrospinal fluid for bilirubin in suspected 
Nagy et al.: Diagnosis of subarachnoid haemorrhage      2083
subarachnoid haemorrhage: interpret with caution. J Clin Pathol 
2009;62:1052.
71. Chalmers AH, Kiley M. Detection of xanthochromia in 
cerebrospinal fluid. Clin Chem 1998;44:1740–2.
72. Viljoen A, Walker SW, Walker KS, Twomey PJ. Imprecision 
of cerebrospinal fluid net bilirubin absorbance. Clin Chem 
2004;50:1266–8.
73. Collet N, Garcelon N, Robbe V, Lucas-Clerc C, Cuggia M, 
Bendavid C. Bioinformatic software for cerebrospinal fluid 
spectrophotometry in suspected subarachnoid haemorrhage. 
Ann Clin Biochem 2012;49:177–83.
74. Viljoen A, Walker KS, Ho C, Twomey PJ. Analysis of cerebrospinal 
fluid for suspected subarachnoid haemorrhage is improved by 
built-in spectrophotometer software. J Clin Pathol 2006;59:667.
75. O’Connell DM, Watson ID. Definitive angiographic detection 
of subarachnoid haemorrhage compared with laboratory 
assessment of intracranial bleed in CT-negative patients. Ann 
Clin Biochem 2003;40:269–73.
76. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R.  
Ultra-early rebleeding in spontaneous subarachnoid 
hemorrhage. J Neurosurg 1996;84:35–42.
77. Mark DG, Pines JM. The detection of nontraumatic subarachnoid 
hemorrhage: still a diagnostic challenge. Am J Emerg Med 
2006;24:859–63.
78. Eggers C, Liu W, Brinker G, Fink GR, Burghaus L. Do negative 
CCT and CSF findings exclude a subarachnoid haemorrhage? 
A retrospective analysis of 220 patients with subarachnoid 
haemorrhage. Eur J Neurol 2011;18:300–5.
Karin Nagy has just received her Medical Degree from the Univer-
sity of Gothenburg and is currently on her internship to become a 
licensed physician. The review “Cerebrospinal fluid analyses for 
the diagnosis of subarachnoid haemorrhage and experience from 
a Swedish study” is a part of the research she did for her medical 
thesis.
Ina Skagervik is a Neurosurgical Resident since 2009 at Sahlgren-
ska University Hospital, Gothenburg, Sweden. She received her 
Medical Degree in 2006. She is clinically active in various neurosur-
gical fields in order to complete her specialist competence in neuro-
surgery in 2014. She recently started research in different methods 
of diagnosing subarachnoid haemorrhage in cerebrospinal fluid.
Hayrettin Tumani received his Medical Degree from the University 
of Göttingen in 1991. He received board certification in Neurology in 
1999 and completed his habilitation thesis, “Brain-specific proteins 
in CSF: physiology and clinical relevance”, in 2001. Dr. Tumani is 
a Professor of Neurology and the Director of the Multiple Sclerosis 
Center at the Department of Neurology, University School of Medi-
cine, Ulm, Germany. He is also the Director of the CSF Laboratory, 
and past president of the German Society of CSF Analysis and Clini-
cal Neurochemistry (DGLN). His scientific areas of interest include 
diagnostic and prognostic biomarkers in multiple sclerosis as well 
as in neurodegenerative diseases such as amyotrophic lateral 
sclerosis.
Axel Petzold graduated from the Medical University of Freiburg 
(Germany). He received his MD (summa cum laude) in Experimental 
Ophthalmology with Ted Sharpe (University of Freiburg) and his PhD 
in Biochemistry with Ed Thompson (University College London). He 
trained as a neurologist in France (Lyon), Germany (Munich), and 
the UK (London). He now works as Consultant Neurologist at the VU 
Medical Center Amsterdam and as an Honorary Senior Lecturer at 
the UCL Institute of Neurology, Queen Square. His research interest 
is on axonal degeneration mainly in multiple sclerosis and optic 
nerve disease and also other diseases and models he can learn 
from.
2084      Nagy et al.: Diagnosis of subarachnoid haemorrhage
Manfred Wick graduated from the Medical School of Ludwig 
Maximilian University of Munich. He is now a consultant laboratory 
physician for the Department of Neurology, Klinikum Großhadern, 
University of Munich. Since 1994, he is a senior physician and assis-
tant laboratory director with special interest in immunology, CSF 
analysis, and iron metabolism. He is a member of the Board of the 
German Society for CSF Analysis and Clinical Neurochemistry, and 
since 2002, he is a member of the Educational Commission.
Hans-Jürgen Kühn was born in 1944 in Sommerfeld (now called 
Lubsko). Since 1945, he has been is living in Leipzig. After school, 
he studied chemistry at the University of Leipzig and finished it 
1969, receiving a “Diplomchemiker” degree. In 1970, he started 
his career in the field of clinical chemistry. From 1975 to 2009, he 
was the head of the CSF Laboratory at the Medical Department 
of the University of Leipzig. In 1982, he defended a dissertation 
about copper metabolism in Wilson disease. He is a member of the 
German Society of Clinical Chemistry (DGKL) and foundation and 
honor member of the German Society of CSF Diagnosis and Clinical 
Neurochemistry (DGLN).
Manfred Uhr is the assistant medical director and head of the 
Neurological Outpatient Clinic, head of the Department of Clinical 
Neurophysiology (EEG, evoked potentials, EMG, sonography), and 
head of the Neurochemical Laboratory comprising the conduction 
of CSF analyses, therapeutic drug monitoring, hormone detection, 
and further laboratory parameters required for the diagnosis of 
neurological and psychiatric diseases at the Max Planck Institute of 
Psychiatry. One of the aims of the research group is to investigate 
the influence of the blood-brain barrier on the etiology and therapy 
of neurological and psychiatric diseases. The group’s interest 
has been focused on transport proteins carrying their substrates 
against a concentration gradient from the brain back into the blood, 
thus influencing the endocrinological regulatory circuit and the 
pharmacokinetics of drugs acting on the CNS.
Axel Regeniter, MD, PhD, is the deputy director of clinical chemis-
try at Basel’s University Hospital. His area of expertise is protein 
biochemistry, where analysis results are usually complex, inter-
related, and difficult to interpret. He developed a knowledge-based 
system that combines text output with visually oriented report 
forms to transfer the information from the laboratory to the clinical 
ward most effectively. The original system for the differentiation 
of proteinuria is available in five languages and in routine use in 
over 100 laboratories. Ongoing development led to the creation of 
“Visual MDI Lablink”, which applies this to many different areas 
of laboratory medicine, for instance, cerebrospinal fluid analysis, 
protein electrophoresis and immunofixation, neurological auto 
antibodies, chimerism, or the assessment of nutritional status. In 
his spare time, he loves to participate in outdoor activities like golf 
and skiing.
Johannes Brettschneider received his medical training at the Univer-
sity of Tuebingen, Germany. He is a neurologist with special inter-
ests in electromyography, palliative care, and geriatrics. In 2011, he 
was a visiting associate professor at the University of Pennsylvania 
Center of Neurodegenerative Disease Research (CNDR).
Markus Otto is a professor of neurology at the University of Ulm, the 
elected president of German Society of CSF Diagnostics and Neuro-
chemistry (www.dgln.de), and speaker of the German Consortium 
for Frontal Lobar Degenerations (www.ftld.de), which is supported 
Nagy et al.: Diagnosis of subarachnoid haemorrhage      2085
by the German Ministry of Science and Development. His focus lies 
on the development and evaluation of methods and markers for the 
early and differential diagnosis of neurodegenerative diseases and 
in the investigation of the roles of these proteins in models of these 
diseases.
Jörg Kraus, MD, completed his primary and secondary education 
in Weiden, Germany, and studied medicine at the University of 
Regensburg (November 1990 to September 1992) and the Justus-
Liebig University of Giessen (October 1992 to November 1997). He 
completed his MD thesis in 2000. The title of his thesis was “ICAM 
1, ICAM 3, and CD45RA in cerebrospinal fluid and blood as activity 
parameters in multiple sclerosis”. He subsequently received his 
“Venia Legendi” at the Paracelsus Private Medical University of 
Salzburg, having completed his habilitation thesis “The impact of 
interferon-treatment on the blood-brain barrier”. Since 1995, Dr. 
Kraus has been working at the MS outpatient departments of three 
different university hospitals.
Florian Deisenhammer is presently a professor of neurology at the 
University of Innsbruck in Austria. After graduating in 1989 from the 
University of Vienna Medical School, he finished his training in clini-
cal neurology at Innsbruck Medical University in 1996 and became 
a senior staff member since then. He is the director of the Neuroim-
munological Laboratory, and his clinical work focuses on stroke 
and neuroimmunology, particularly multiple sclerosis. His main 
scientific interest is MS therapy monitoring, specifically antibodies 
against interferons and other biomarkers in CSF and blood. He is 
a member of various international and national societies including 
the Austrian Medical Society, the International Society of Neuro-
immunology, the EFNS Task Force on Beta Interferon Neutralizing 
Antibodies, board member of the German Society of Neurochemistry 
and CSF Diagnostics, the Task Force on CSF, and member of the edi-
torial board of the Journal Multiple Sclerosis and Related Disorders 
(MSARD).
Ronald Lautner is a medical doctor and researcher. He received his 
medical education at Innsbruck Medical University, Austria. He is 
now a physician in specialist training (clinical chemistry) at Sahlg-
renska University Hospital, and a PhD student at the research team 
on “Neurochemical Pathogenesis and Diagnostics” at the Depart-
ment of Neuroscience and Physiology, University of Gothenburg, 
Sweden. His research is focused on cerebrospinal fluid biomarkers 
in the clinical diagnosis of Alzheimer disease and other brain disor-
ders, including neuroinflammation and brain injury.
Kaj Blennow took his medical degree (MD) in 1984 and holds a 
specialist competence in both general psychiatry and in clini-
cal chemistry. He is the head of the Clinical Neurochemistry Lab 
at Sahlgrenska University Hospital, Gothenburg, Sweden, and a 
professor of clinical neurochemistry at the Sahlgrenska Academy, 
Mölndal campus at the University of Gothenburg, Sweden. His major 
research areas are cerebrospinal fluid biochemical markers, clinical 
proteomics, and the neurochemical pathogenesis of Alzheimer 
disease and other brain disorders. Blennow has published more 
than 550 original research papers and 80 review articles in peer-
reviewed journals and has an ISI Web of Knowledge H-index of 71 
(March 2013). He has received a number of scientific awards, such 
as the CINP Award (1992), the IPA Research Award (1993), the Alois 
Alzheimer Research Award (2001), the ECNP Clinical Research Award 
(2010), and the Henry Wisniewski Lifetime Achievement Award in 
Alzheimer’s Disease Research (2011).
Leslie Shaw is a professor at the Department of Pathology and Lab 
Medicine at Hospital of the University of Pennsylvania. In 1968, he 
received his PhD in biochemistry. He has received several awards, 
honors, and membership in honorary societies since then. Leslie 
Shaw has published more than 200 original research papers 
and review articles in peer-reviewed journals. His main scientific 
2086      Nagy et al.: Diagnosis of subarachnoid haemorrhage
interests are biomarkers in Alzheimer disease. He is also a member 
of the NCCLS Area Committee on Toxicology and Drug Monitoring 
(1989 to present).
Henrik Zetterberg has a background in molecular biology and 
clinical chemistry and has spent the last 10 years focusing on the 
development of biomarkers for Alzheimer disease and other brain 
disorders. His research is translational and the biomarkers are 
evaluated in cell and animal models, as well as in longitudinal 
studies of patients and healthy individuals. He has developed new 
diagnostic tests for Alzheimer disease, as well as new preclini-
cal models, and has shown that myeloid pathology precedes τ 
pathology around 5 years during the Alzheimer disease process in 
humans, that altered amyloid homeostasis in the brain is evident 
already in presymptomatic stages of the disease, and that the 
diagnostic usefulness of AD biomarkers decreases with age due to 
increased prevalence of preclinical Alzheimer neuropathology.
Niklas Mattsson is a medical doctor and researcher. He is a certified 
specialist in clinical chemistry and is currently doing postdoctoral 
research at the University of California San Francisco in the group 
of Michael W. Weiner. His research is focused on biomarkers for 
neurological diseases, especially cerebrospinal fluid and imaging 
markers for neurodegenerative diseases. He received his medical 
education in Lund and Gothenburg (Sweden) and did his doctorate 
studies at the University of Gothenburg, studying cerebrospinal 
fluid biomarkers for axonal degeneration and amyloid metabolism 
in Alzheimer disease, neuroinflammation, and inborn errors of 
metabolism.
